Physician profile
William Touchstone
NPI 1245249184
$3,738.33
in general payments reported to CMS, 2019-2025
18 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $237 · 2021: $588 · 2022: $642 · 2023: $699 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.80 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $992.21 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $563.29 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $551.93 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $303.28 | 2020-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $270.11 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $263.34 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $236.01 | 2019-2023 | Ingrezza |
| Abbvie INC. | $162.34 | 2022-2025 | |
| Lundbeck LLC | $155.01 | 2019-2023 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $59.30 | 2019-2023 | Uzedy |
| Allergan, INC. | $57.65 | 2019 | |
| Indivior INC. | $26.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.95 | 2025 | Cobenfy |
| Shire North American Group INC | $18.93 | 2019 | |
| Acadia Pharmaceuticals INC | $18.33 | 2025 | Daybue |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $14.16 | 2025 | |
| Ironshore Pharmaceuticals INC. | $12.72 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Touchstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.